



First quarter 2011
Press and analyst presentation
13 April 2011

RENCAREX®

- 343 relapses in the ARISER trial
- Start process for interim analysis for efficacy

REDECTANE®

- Filing with FDA in preparation

MESUPRON®

- Patient recruitment Phase II breast cancer trial close to completion

Corporate & Commercial


- Integration of WILEX Inc. into the WILEX Group completed
- Acquisition of Heidelberg Pharma AG completed
- Shareholder loan secures additional financing




Financial review Q1 2011

Sales revenue and other income 2011


*€ '000 ; rounded



*€ '000 ; rounded



*€ '000 ; rounded



→ **First sales revenue from WILEX Inc.**



→ **Other income lower than previous year**

→ Prepayments accrued and recognised in line with positive project progress


→ **Number of employees increased from 70 to 74 (incl. WILEX Inc.)**

Operating expenses 2011

*€ m; rounded



*€ m; rounded



→ **Operating expenses up 4.2% compared to Q1 2010**

→ higher administrative costs of € 60k for operational launch of WX Inc. and EGM


→ **R&D expenses 75 % of total costs**

→ **Net loss for the period higher than previous year and in line with guidance**


→ **EPS of € -0.32 (Q1 2010: € -0.34 due to lower share capital)**

Balance sheet as at 30 November 2010


*€ m; rounded



*€ m; rounded



*€ m; rounded



→ Total assets at € 8.27m above previous year

→ Cash balance as at 28.02.2011 € 4.62 m

→ € 10.0 m shareholder loan

→ Average cash usage per month € 2.44 m (Q1 2010: € 2.07 m)

→ Equity was € -7.21 million (without the contribution in kind capital increase through Heidelberg Pharma)



Guidance 2011

In € m	Guidance 2011	2010
Sales and other income	3.0 – 4.5	1.3
Operating expenses	28.0 – 33.0	24.4
- Of which R&D	22.0 – 27.0	19.7
Net loss	24.0 – 29.0	23.1
- Of which WILEX Inc. and Heidelberg Pharma	2.0 – 3.0	n/a
Usage of cash and cash equivalents	26.0 – 29.0	25.5
Monthly use of cash	2.2 – 2.5	2.06

- **No changes to our guidance**
- **Guidance comprises WILEX AG, WILEX Inc. and Heidelberg Pharma AG**
- **No revenues from licensing deals included**

REDECTANE®

→ Filing with FDA

RENCAREX®

→ Data Interim analysis for efficacy, IDMC recommendation
→ Could be basis for filing with EMA

MESUPRON®


→ Completion of patient recruitment Phase II breast cancer trial

WX-554

→ Start of trials in patients

Corporate &
Commercial

→ Integration of Heidelberg Pharma
→ ADC technology licensing deal
→ Licensing deal for WILEX's product candidates
→ Secure additional financing



¹⁾ dievini Hopp BioTech + related parties

→ Capital raised

- €10m UCB transaction in 02/2009
- €18.5m capital increase in 2009/2010
- €10m shareholder loan in 12/2010

→ Stock Exchange data

- FSE Prime Standard (Ticker symbol: WL6)
- 21,613,035 shares registered (€1.00/per share)

Forward looking statements

This communication contains certain forward-looking statements, relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will", "should", "future", "potential" or similar expressions or by general discussion of strategy, plans or intentions of the Company. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Such factors include, among others, the following: uncertainties related to results of our clinical trials, the uncertainty of regulatory approval and commercial uncertainty, reimbursement and drug price uncertainty, the absence of sales and marketing experience and limited manufacturing capabilities, attraction and retention of technologically skilled employees, dependence on licenses, patents and proprietary technology, dependence upon collaborators, future capital needs and the uncertainty of additional funding, risks of product liability and limitations of insurance, limitations of supplies, competition from other biopharmaceutical, chemical and pharmaceutical companies, environmental, health and safety matters, availability of licensing arrangements, currency fluctuations, adverse changes in governmental rules and fiscal policies, civil unrest, acts of God, acts of war, and other factors referenced in this communication.

Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.

This material is not intended as an offer or solicitation for the purchase or sale of shares of WILEX AG. This material may not be distributed within countries where it may violate applicable law.

→ Financial calendar 2011

- 18 May Annual General Meeting 2011
- 14 July Half-yearly Financial Report 2011
- 13 October 9-month Financial Report 2011

WILEX AG

Grillparzerstr. 10
81675 Munich, Germany
Tel.: +49 (0)89-41 31 38-0
Fax: +49 (0)89-41 31 38-99
Website: www.wilex.com

Corporate Communications

Katja Arnold (CIRO)
Email: [investors\[at\]wilex.com](mailto:investors[at]wilex.com)
Tel.: +49 (0)89-41 31 38-126

ISIN: DE0006614720
Symbol: WL6
Reuters: WL6G.DE
Bloomberg: WL6G.GR